Last reviewed · How we verify
Standard vaccination schedule
A standard vaccination schedule stimulates the immune system to produce antibodies and cellular immunity against specific infectious diseases through sequential administration of vaccines.
A standard vaccination schedule stimulates the immune system to produce antibodies and cellular immunity against specific infectious diseases through sequential administration of vaccines. Used for Prevention of infectious diseases including diphtheria, tetanus, pertussis, poliomyelitis, measles, mumps, rubella, hepatitis B, and other vaccine-preventable diseases.
At a glance
| Generic name | Standard vaccination schedule |
|---|---|
| Sponsor | Universidade Federal de Goias |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Vaccination schedules consist of multiple doses of vaccines administered at defined intervals to build and maintain protective immunity against targeted pathogens. The schedule is designed to optimize immune response by allowing time between doses for immune memory development, and to provide protection during critical periods of vulnerability across the lifespan.
Approved indications
- Prevention of infectious diseases including diphtheria, tetanus, pertussis, poliomyelitis, measles, mumps, rubella, hepatitis B, and other vaccine-preventable diseases
Common side effects
- Local injection site reactions (pain, redness, swelling)
- Fever
- Myalgia
- Fatigue
- Headache
Key clinical trials
- HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
- Extended Dosing Intervals Trial for Oral Cholera Vaccine, Kenya (PHASE4)
- Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM (PHASE1)
- Increasing Measles Vaccination Coverage Through Supplementation With an SQ-LNS Incentive in Children Aged 6-23 Months (NA)
- Group Postpartum and Well-Child Care for Maternal and Infant Health (NA)
- Efficacy of Mobile Health Application in Promotion of Exclusive Breast Feeding and Young Child Feeding Practices in Pakistan (NA)
- Trial of Additional Measles Vaccine to Reduce Child Mortality (PHASE4)
- Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard vaccination schedule CI brief — competitive landscape report
- Standard vaccination schedule updates RSS · CI watch RSS
- Universidade Federal de Goias portfolio CI